title: Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration.
abstract: In the planning of MRI protocols to monitor disease activity in multiple sclerosis (MS), the clinical subtype needs to be considered. In this serial gadolinium-enhanced MRI study, we demonstrated differences between patients with early relapsing/remitting MS and benign MS in both the production of new lesions and the occurrence of enhancement.
authors.affiliation: NMR Research Group, Institute of Neurology, Queen Square, London, England.
authors.forename: A J
authors.initials: AJ
authors.lastname: Thompson
authors.forename: D
authors.initials: D
authors.lastname: Miller
authors.forename: B
authors.initials: B
authors.lastname: Youl
authors.forename: D
authors.initials: D
authors.lastname: MacManus
authors.forename: S
authors.initials: S
authors.lastname: Moore
authors.forename: D
authors.initials: D
authors.lastname: Kingsley
authors.forename: B
authors.initials: B
authors.lastname: Kendall
authors.forename: A
authors.initials: A
authors.lastname: Feinstein
authors.forename: W I
authors.initials: WI
authors.lastname: McDonald
mesh_terms: D000328:Adult; D003287:Contrast Media; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000503:physiopathology; D009942:Organometallic Compounds; D004369:Pentetic Acid; D012008:Recurrence; D013997:Time Factors
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D019786:Gadolinium DTPA